Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Current Deferred Revenue data on record, last reported at $23.4 million in Q2 2025.

  • For Q2 2025, Current Deferred Revenue fell 1.24% year-over-year to $23.4 million; the TTM value through Jun 2025 reached $23.4 million, down 1.24%, while the annual FY2024 figure was $17.6 million, 31.37% down from the prior year.
  • Current Deferred Revenue reached $23.4 million in Q2 2025 per TNGX's latest filing, up from $19.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $34.0 million in Q1 2023 and bottomed at $15.6 million in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $25.7 million, with a median of $25.8 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: soared 35.91% in 2023, then crashed 42.37% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $26.0 million in 2021, then grew by 22.17% to $31.8 million in 2022, then decreased by 19.26% to $25.7 million in 2023, then plummeted by 31.37% to $17.6 million in 2024, then skyrocketed by 32.67% to $23.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $23.4 million in Q2 2025, $19.5 million in Q1 2025, and $17.6 million in Q4 2024.